{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046064","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.366669+00:00","generated_at":"2026-05-24T04:19:01.672614+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tyra Biosciences reports $86.5M net loss for 2024; cash runway through 2027; three INDs cleared","bullets":["Cash, equivalents, and marketable securities $341.4M at YE 2024 (up from $203.5M), providing runway through at least 2027.","Full-year 2024 net loss $86.5M vs $69.1M in 2023; R&D expenses $80.1M vs $62.5M.","TYRA-300 showed 54.5% confirmed PR (6/11) at ≥90mg QD in FGFR3+ mUC patients (SURF301).","Three INDs cleared: TYRA-300 Phase 2 for NMIBC (SURF302) and ACH (BEACH301), and TYRA-430 Phase 1 (SURF431).","First patient dosing expected Q2 2025 for BEACH301 (achondroplasia), SURF302 (NMIBC), and SURF431 (HCC)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046064","json":"https://secwatch.observer/filing/0000950170-25-046064.json","markdown":"https://secwatch.observer/filing/0000950170-25-046064.md","text":"https://secwatch.observer/filing/0000950170-25-046064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/0000950170-25-046064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025046064/tyra-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:19:01.672614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}